Combination therapy of lamotrigine and escitalopram may cause myoclonus [9]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 3, 2006, Pages 346-347

  Rosenhagen, Marcus C ^a   Schmidt, Ulrike ^a   Weber, Frank ^a   Steiger, Axel ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; ESCITALOPRAM; FLUOXETINE; LAMOTRIGINE; LEVODOPA; NIFEDIPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VERAPAMIL;

ADULT; BIPOLAR II DISORDER; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; LETTER; MYOCLONUS; PRIORITY JOURNAL; SEIZURE; SEROTONIN SYNDROME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIMANIC AGENTS; CITALOPRAM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MYOCLONUS; TRIAZINES;

EID: 33744465015     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000219927.49799.c0     Document Type: Letter

References (13)

1. Jimenez-Jimenez FJ, Puertas I, de Toledo-Heras M. Drug-induced myoclonus: frequency, mechanisms and management. CNS Drugs. 2004;18:93-104.
2. Vadlamudi L, Wijdicks FM. Multifocal myoclonus due to verapamil overdose. Neurology. 2002;58:984-985.
3. Janszky J, Rasonyi G, Halasz P, et al. Disabling erratic myoclonus during lamotrigine therapy with high serum level - report of two cases. Clin Neuropharmacol. 2000;23:86-89.
4. Hahn SJ, Choi J-S, Rhie D-J, et al. Inhibition by fluoxetine of voltage-activated ion channels in rat PC12 cells. Eur J Pharmacol. 1999;367:113-118.
5. Spigset O, Hedenmalm K, Dahl ML, et al. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand. 1997;96:379-384.
6. Von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, a comparison to R-citalopram. Drug Metab Dispos. 2001;29:1102-1109.
7. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-1120.
8. Staedt J, Stoppe G, Riemann H, et al. Lamotrigine in the treatment of nocturnal myoclonus syndrome (NMS): two case reports. J Neural Transm. 1996;103:355-361.
9. Russell HH, Svensson E, Dewael Y, et al. 5HT inhibits N-type but not L-type Ca 2+ channels via 5-HT1A receptors in lamprey spinal neurons. Eur J Neurosci. 2003;18:2919-2924.
10. Vinod KY, Subhash MN. Lamotrigine induced selective changes in 5-HT1A receptor mediated response in rat brain. Neurochem Int. 2002;40:315-319.
11. Erfurth A, Amann B, Grunze H. Female genital disorder as adverse symptom of lamotrigine treatment. A serotonergic effect? Neuropsychobiology. 1998;38(3):200-201.
12. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure. 1998;7:163-165.
13. Ernst CL, Goldberg JF. Antidepressant properties of anticonvulsant drugs for bipolar disorder. J Clin Psychopharmacol. 2003;23:182-192.